Figure 9
The effects of PNU-282987 in vitro and in vivo are blocked by intravitreal administration of SR95531, a selective GABAA receptor antagonist. (A) FluoroGold labeling of surviving RGCs in the central (top panel) and peripheral (bottom panel) regions of retina. The images were obtained at high magnification (scale bar, 50 μm). Administration of SR95531 decreases the effects of PNU-282987 on RGC viability. (B) Quantification of RGC survival in control and glaucomatous retinas following treatment with the vehicle, PNU-282987, SR95531, and SR95531 + PNU-282987 (n = 7). *p < 0.05, **p < 0.01, ***p < 0.001 (one-way analysis of variance). (C) Representative TUNEL (red), Brn3a (green), Hoechst (blue), and merged confocal microscopic images of the ganglion cell layer. All images were obtained at the same magnification. Scale bars, 20 μm. (D) Quantification of the PhNR amplitude in glaucomatous retinas of eyes treated with SR95531 or SR95531 + PNU-282987 relative to eyes treated with PNU-282987. **p < 0.01, ***p < 0.001 (Student’s paired t test). The results in B and D are expressed as the mean ± SE. OHT, ocular hypertension.
